Advances in Pharmacology & Clinical Trials (APCT)

ISSN: 2474-9214

Mini Review

Hepatokines as Biomarkers of Obesity-Associated Liver Pathophysiology: Deciphering Advances in Basic and Clinical Aspects

Authors: Ishtiaq SM1* and Bashir T2

DOI: 10.23880/apct-16000228

Abstract

Hepatokines are specialized secretory proteins of the liver that play pivotal role in regulation of metabolic homeostasis as well as ensure crosstalk of liver to other organs. In recent years, the correlation of hepatokines and hepatic diseases has been exhibited, positively. Several stimuli, particularly hepatic steatosis provoke dysregulation in metabolic homeostasis and subsequently, pathogenesis of liver diseases that influence expression and release of hepatokines. In this review, we have interlinked the association of hepatic steatosis, a hallmark of obesity, to liver and liver-derived hepatokines. Furthermore, we summarized briefly the impact of several etiologically and epidemiologically important hepatokines, including Fetuin-A, fibroblast growth factor-21 (FGF-21), selenoprotein P, sexual hormone binding globulin (SHBG), angiopoietin like 4 (ANGPTL4) and leukocyte cell-derived chemotaxin (LECT2), in health and disease. Such hepatokines could serve as non-invasive biomarkers of early stages of liver pathogenesis and might contribute in improving patient safety profile for screening purposes and expediting drug development.

Keywords: Hepatokines; Obesity; Liver Pathophysiology; Liver Diseases; Cellular Crosstalk

View PDF

Google_Scholar_logo Academic Research index asi ISI_logo logo_wcmasthead_en scilitLogo_white F1 search-result-logo-horizontal-TEST cas_color europub infobase logo_world_of_journals_no_margin